scholarly journals UNDERSTANDING THE MECHANISM OF ACTION OF INTRAVENOUS IMMUNOGLOBULINS: A TEN YEARS EXPERIENCE IN TREATING GUILLAIN BARRÉ SYNDROME

FARMACIA ◽  
2020 ◽  
Vol 68 (3) ◽  
pp. 426-435
Author(s):  
ADINA STOIAN
Keyword(s):  
Mechanism Of Action ◽  
Intravenous Immunoglobulins ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Reworsening of Recurrent Guillain-Barré Syndrome Triggered by COVID-19 Infection

2021 ◽  
Vol 15 (1) ◽  
pp. 48-51
Author(s):  
Gian Luca Vita ◽  
Carmen Terranova ◽  
Maria Sframeli ◽  
Antonio Toscano ◽  
Giuseppe Vita
Keyword(s):  
Viral Infection ◽  
Neurological Diseases ◽  
Intravenous Immunoglobulins ◽  
Guillain Barre Syndrome ◽  
Case Presentation ◽  
Appropriate Treatment ◽  
Immune Mediated ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Introduction: Guillain-Barré Syndrome (GBS) is an acute, immune-mediated, generalized polyradiculoneuropathy often triggered by a bacterial or viral infection, vaccination, or surgery. During the SARS-CoV-2 pandemic, some patients were reported with GBS associated COVID-19 infection. Case Presentation: We report, herein, a patient who had a recurrent GBS after forty years. Intravenous immunoglobulins (IVIg) induced improvement, but her condition worsened suddenly after twenty days, coinciding with a COVID-19 infection. A second IVIg cycle was administered, and she improved again. Conclusion: The take-home message is that in the current pandemic, any re-worsening or lack of improvement after appropriate treatment of GBS or possibly other autoimmune neurological diseases must be checked to determine if it is related to COVID-19 infection.

scholarly journals Guillain–Barré syndrome: pathophysiology, etiology, causes, and treatment

2021 ◽  
Author(s):  
Rahmathulla S. Rahman ◽  
Moayyad S. Bauthman ◽  
Amer M. Alanazi ◽  
Naif N. Alsillah ◽  
Ziyad M. Alanazi ◽  
...  
Keyword(s):  
Literature Review ◽  
Peripheral Nerves ◽  
Neuromuscular Junctions ◽  
Molecular Mimicry ◽  
Intravenous Immunoglobulins ◽  
Guillain Barre Syndrome ◽  
Gastrointestinal Infections ◽  
Serious Adverse Events ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Guillain–Barré syndrome (GBS) is a polyradiculoneuropathy autoimmune disease that is characterized by significant inflammation that affects the peripheral nervous system in a rapidly progressive pattern that is mainly clinically presented by muscle weakness. The present literature review aims to broadly discuss GBS: etiology, pathophysiology and management in order to gain an understading of the existing studies that are relevant to this literature review. Among the reported antibodies, anti-GM1 and anti-GQ1B have been reported to be responsible for attacking and damaging either the neuromuscular junctions or peripheral nerves. Moreover, it has been found that the anti-GD1a antibodies in patients bind to the neuromuscular junction and also bind to the nodes of Ranvier of the peripheral nerves and the paranodal myelin of the affected nerves. Reports have shown that this disease is identified as special forms of neuropathies that develop in immune-mediated, post-infection sequelae. Furthermore, in another study it was reported that Molecular mimicry has been previously reported to significantly correlate with the development of the disease as it was investigated in animal models. In addition, Campylobacter jejuni, a pathogen that causes gastrointestinal infections has been previously reported to predispose to the development of GBS in humans. However, scientists have found that plasma exchange and intravenous immunoglobulins (IVIG) remain the most significant and efficacious factors in managing the disease. Nevertheless, recent trials have investigated other approaches that are less efficacious and can lead to serious adverse events and complications. 

scholarly journals Guillain-Barre Syndrome following COVID-19 Infection: First Case Report from Kuwait and Review of the Literature

2021 ◽  
pp. 1-5
Author(s):  
Walaa A. Kamel ◽  
Ismail Ibrahim Ismail ◽  
Jasem Yousef Al-Hashel
Keyword(s):  
Intravenous Immunoglobulins ◽  
Lower Limbs ◽  
Guillain Barre Syndrome ◽  
Global Pandemic ◽  
First Case ◽  
Immune Mediated ◽  
Guillain Barré Syndrome ◽  
Electrophysiological Studies ◽  
History Of ◽  
Guillain Barré

Objective: Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that is often related to a previous infectious exposure. GBS emerged as a potentially serious complication of coronavirus disease 2019 (COVID-19) since its declaration as a global pandemic. We report the first case from Kuwait, to the best of our knowledge. Clinical Presentation: A 72-year-old male presented with 3 weeks history of acute progressive and ascending lower limbs weakness. He developed these symptoms 3 weeks after testing positive to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Electrophysiological studies showed acute demyelinating polyradiculoneuropathy and cerebrospinal fluid showed protein-cell dissociation. He was successfully treated with intravenous immunoglobulins (IVIGs). Conclusion: Neurologists should be aware of GBS as a potentially serious complication associated with CO­VID-19. Our patient had a favorable outcome with IVIG with no autonomic or respiratory affection.

scholarly journals Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jakob Rath ◽  
Gudrun Zulehner ◽  
Bernadette Schober ◽  
Anna Grisold ◽  
Martin Krenn ◽  
...  
Keyword(s):  
Clinical Improvement ◽  
Real World ◽  
Intravenous Immunoglobulins ◽  
Guillain Barre Syndrome ◽  
Fisher Syndrome ◽  
Treatment Practice ◽  
Guillain Barré Syndrome ◽  
Multiple Treatments ◽  
Guillain Barré

AbstractThis study investigated treatment characteristics of Guillain-Barré syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale > 2 at nadir) and aimed to detect clinical factors associated with multiple treatments. We included 121 patients (74 male; median age 48 [IQR 35–60]) with sensorimotor (63%), pure motor (15%), pure sensory (10%) and localized GBS (6%) as well as Miller Fisher syndrome (6%). 44% of patients were severely affected. All but one patient received at least one immunomodulatory treatment with initially either intravenous immunoglobulins (88%), plasma exchange (10%) or corticosteroids (1%), and 25% of patients received more than one treatment. Severe GBS but not age, sex, GBS subtype or date of diagnosis was associated with higher odds to receive more than one treatment (OR 4.22; 95%CI 1.36–13.10; p = 0.01). Receiving multiple treatments had no adjusted effect (OR 1.30, 95%CI 0.31–5.40, p = 0.72) on clinical improvement between nadir and last follow-up in patients with severe GBS. This treatment practice did not change over the last 20 years.

scholarly journals Melanomatous Leptomeningeal Carcinomatosis masquerading as Guillain-Barré Syndrome

2010 ◽  
Vol 9 (1) ◽  
pp. 20-23
Author(s):  
James R Noake ◽  
◽  
Andrew Shepherd ◽  
William R Smith ◽  
◽  
...  
Keyword(s):  
Intravenous Immunoglobulins ◽  
Rapid Onset ◽  
Leptomeningeal Carcinomatosis ◽  
Guillain Barre Syndrome ◽  
High Dose ◽  
Limb Weakness ◽  
Protein Levels ◽  
Csf Analysis ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

A 49 year old man presented with rapid onset paraparesis, evidence of lower motor neurone features and sensory impairment following a respiratory tract infection. Initially he was treated with intravenous immunoglobulins for suspected Guillain-Barré syndrome (GBS). Subsequent cerebrospinal fluid (CSF) analysis identified unexpectedly high protein levels (attributable to Froin’s syndrome1) and magnetic resonance imaging (MRI) was highly suggestive of leptomeningeal carcinomatosis and cerebral metastases secondary to disseminated malignant melanoma. The disease progressed with rapid deterioration despite high dose corticosteroids and the patient died 12 days after admission. This case brings several key points to the attention of the acute physician, in particular the need to give serious consideration to the differential diagnosis of cancer in a patient presenting with lower limb weakness.

scholarly journals Intravenous immunoglobulins versus plasma exchange in the treatment of Guillain-Barré syndrome

Critical Care ◽  
2009 ◽  
Vol 13 (Suppl 1) ◽  
pp. P108
Author(s):  
B Charra ◽  
A Hachimi ◽  
A Benslama ◽  
S Motaouakkil
Keyword(s):  
Plasma Exchange ◽  
Intravenous Immunoglobulins ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals New clinical manifestations of COVID-19 related Guillain Barre syndrome higly responsive to intravenous immunoglobulins: two italian cases

2020 ◽  
Author(s):  
Andrea Assini ◽  
Luana Benedetti ◽  
Di Maio Silvia ◽  
Schirinzi Erika ◽  
Massimo Del Sette
Keyword(s):  
Clinical Manifestation ◽  
Axonal Neuropathy ◽  
Clinical Manifestations ◽  
Intravenous Immunoglobulins ◽  
Overlap Syndrome ◽  
The Other ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Abstract Recently, some cases of Guillain Barré syndrome (GBS) and Miller Fisher (MF) have been reported, following COVID-19 infection1-2-3 . We report two different clinical manifestation of Covid-19 related GBS , one is a GBS/MF overlap syndrome, the other one an Acute Motor Sensory Axonal Neuropathy (AMSAN) with massive vegetative impairment, both highly responsive to intravenous immunoglobulins.

Sign in / Sign up

Export Citation Format

Share Document